Drug intelligence / Profile preview

RG-BCMA

Development stage: Unknown
Lead developer: Hangzhou Ronggu Biotechnology
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

RG-BCMA is an investigational, universal (allogeneic) chimeric antigen receptor natural killer (CAR-NK) cell therapy developed by Hangzhou RonGu Biotechnology. It is engineered using a lentiviral vector to express a nanobody-based CAR targeting B-cell maturation antigen (BCMA; TNFRSF17). RG-BCMA is designed to recognize and selectively eliminate BCMA-expressing malignant plasma cells in patients with multiple myeloma (bone marrow cancer). An investigator-initiated clinical trial (IIT) for the candidate has been ongoing since late 2024.

Targets

BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on RG-BCMA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RG-BCMA.

Explore the full profile